<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00784537</url>
  </required_header>
  <id_info>
    <org_study_id>IIL-HD0801</org_study_id>
    <secondary_id>EudracT Number 2008−002684−14</secondary_id>
    <nct_id>NCT00784537</nct_id>
  </id_info>
  <brief_title>High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients</brief_title>
  <acronym>HD0801</acronym>
  <official_title>Early Salvage With High Dose Chemotherapy and Stem Cell Transplantation in Advanced Stage Hodgkin's Lymphoma Patients With Positive PET After Two Courses of ABVD (PET-2 Positive) and Comparison of RT Versus no RT in PET-2 Negative Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to define an improvement in patients:

        -  To evaluate if patients resistant to the initial treatment for residual PET-positive
           masses after the first two courses of ABVD (PET-2 positive), can be salvaged by early
           shift to high-dose chemotherapy supported by stem cell rescue

        -  To analyse if patients achieving early complete response (PET-2 negative), can be spared
           the adjuvant radiotherapy on areas of initial bulky disease, at the end of the planned
           six courses of ABVD. To answer this question, PET-2 negative patients will be randomized
           between radiotherapy versus no radiotherapy at the end of ABVD therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is composed by two phases:

        1. A phase II multi-centre study evaluating in patients with advanced stage Hodgkin
           lymphoma the efficacy of an early salvage treatment with high-dose chemotherapy followed
           by stem cell transplantation in patients FDG-PET positive after two courses of ABVD
           (PET-2 positive).

        2. A phase III randomised study comparing the efficacy of radiotherapy to the areas of
           initial bulky disease versus no further therapy in PET-2 negative patients in complete
           remission (PET-6 negative) at the end of six courses of ABVD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate if patients resistant to the initial treatment for residual PET-positive masses after the first two courses of ABVD (PET-2 positive), can be salvaged by early shift to high-dose chemotherapy supported by stem cell rescue.</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To analyse if patients achieving early complete response (PET-2 negative), can be spared the adjuvant radiotherapy on areas of initial bulky disease, at the end of the planned six courses of ABVD.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">520</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)
The subsequent treatment will be as it follows:
PET-2 positive patients will be high-dose salvage treatment;
PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).
The following restaging procedures are planned as it follows:
Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.
Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).
PET-6 negative patients will be randomized to first arm:
No radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)
The subsequent treatment will be as it follows:
PET-2 positive patients will be high-dose salvage treatment;
PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).
The following restaging procedures are planned as it follows:
Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.
Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).
PET-6 negative patients will be randomized to second arm:
Adjuvant radiotherapy (30 Gy) on sites of initial bulky disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABVD</intervention_name>
    <description>ABVD courses are scheduled every 28 days:
Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15
ABVD courses are scheduled every 28 days:
Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15
Randomization to Arm A (Observation)</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABVD and Radiotherapy</intervention_name>
    <description>ABVD courses are scheduled every 28 days:
Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15
Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk).</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed Hodgkin's lymphoma of the classical type (nodular lymphocyte
             predominance excluded).

          -  Stage IIB-IV.

          -  Age 18-70.

          -  No prior therapy for Hodgkin's lymphoma

          -  Written informed consent.

          -  ECOG performance status grades 0-3 (see Appendix E).

          -  FDG-PET scan before the initiation of treatment.

        Exclusion Criteria:

          -  Prior therapy for Hodgkin's lymphoma.

          -  Age less than 18 or more than 70.

          -  Other concomitant or prior malignancies, except basal cell skin carcinoma, or
             adequately treated carcinoma in situ of the cervix, or any cancer in complete
             remission for more than 5 years.

          -  HIV infection.

          -  Pregnancy or breast-feeding.

          -  Renal failure (creatinine ≥2 times the normal value), liver failure (AST/ALT or
             bilirubine ≥ 2.5 times the normal value) or heart failure (NYHA class ≥ 2 or FEV &lt;
             45%).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Levis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale SS. Antonio, Biagio e Cesare Arrigo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro di riferimento Oncologico Oncologia Medica A</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Policlinico di Bari - Divisione di Medicina A</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinco Sant'Orsola Isituto di Ematologia ed oncologia Medica</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo SC Oncologia Medica III</name>
      <address>
        <city>Busto Arsizio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Osp.Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Careggi Cattedra di Ematologia</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASLTO4</name>
      <address>
        <city>Ivrea</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Cardinale Panico Divisione di Ematologia Tricase</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda Cà Granda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Avogadro Divisione di Ematologia</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Francesco UO Ematologia e Centro Trapianti</name>
      <address>
        <city>Nuoro</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico San Matteo Clinica Ematologica</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. Santa Maria delle Croci UO Ematologia</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bianchi Melacrino Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. degli Infermi Divisione di Oncologia</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Regina Elena IFO SC Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp.Sant'Eugenio Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università La Sapienza Dipartimento di Biotecnnologie Cellulari</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas Divisione di Oncologia Medica ed Ematologia</name>
      <address>
        <city>Rozzano (MI)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Universitaria di Sassari</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Le Scotte</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Onco-Ematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCC Onco-Ematologia Candiolo</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. San Giovanni Battista_Molinette Ematologia 2</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero universitaria di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL 14 UO Oncologia</name>
      <address>
        <city>Verbania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2008</study_first_submitted>
  <study_first_submitted_qc>November 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2008</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin's lymphoma</keyword>
  <keyword>ABVD</keyword>
  <keyword>FDG-PET (18-Fluoro-deoxy-D-glucose Positron Emission Tomography)</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

